Skip to main content

Advertisement

SpringerLink
Log in

Targeting the endothelin axis in prostate carcinoma

  • Review
  • Published:
Tumor Biology

Abstract

Prostate cancer is the most common malignancy in men in Western countries. Until the last decade, the main available therapeutic options were based on hormonal therapy. For castration-refractory prostate carcinoma, from 2004, the combination of chemotherapy with docetaxel and prednisone has shown to improve survival in this subset of patients. Many agents have been tested either alone or in combination with this standard therapy, trying to find synergistic effects between drugs, and to target specific pathways that influence tumor growth, invasiveness, angiogenesis, and the development of distant metastasis. Endothelin antagonists have been recently studied, as they can get involved in many of these oncogenic pathways, and results are encouraging; nevertheless, the right setting to use them, whether to use them in monotherapy or in combination with other agents, and if they really improve the survival of our patients, are questions that remain to be addressed. In this review, we summarize the role of endothelins in tumoral biology and specifically in prostate carcinoma natural history, and the results obtained in the clinical trials involving this new therapeutic group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  PubMed  CAS  Google Scholar 

  3. Berthold RD, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX327 study. J Clin Oncol. 2008;26:242–5.

    Article  PubMed  CAS  Google Scholar 

  4. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12(20 Suppl):6296s–300s.

    Article  PubMed  CAS  Google Scholar 

  5. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2004;2:16.

    Article  PubMed  Google Scholar 

  6. Obara K, Koide M, Ishikawa T, Tanabe Y, Nakayama K. Protein kinase C δ but not PKC epsilon activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery. J Cardiovasc Pharmacol. 2000;36:S120–1.

    PubMed  CAS  Google Scholar 

  7. Battistini B, Chailler P, D’Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides. 1993;14:385–99.

    Article  PubMed  CAS  Google Scholar 

  8. Nelson JB, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110–6.

    Article  PubMed  CAS  Google Scholar 

  9. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signaling by G-protein-coupled receptors. Nature. 1996;379:557–60.

    Article  PubMed  CAS  Google Scholar 

  10. Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM, Shen R. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Mol Carcinog. 2009;48(2):141–9.

    Article  PubMed  CAS  Google Scholar 

  11. Spinella F, Garrafa E, Di Castro V, Rosano L, Nicotra MR, Caruso A, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 2009;69(6):2669–76.

    Article  PubMed  CAS  Google Scholar 

  12. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer. 2007;14(2):233–44.

    Article  PubMed  CAS  Google Scholar 

  13. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12:6213s–6s.

    Article  PubMed  CAS  Google Scholar 

  14. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci. 2001;21:999–1006.

    PubMed  CAS  Google Scholar 

  15. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med. 2001;2:24–7.

    Article  PubMed  CAS  Google Scholar 

  16. Yuyama H, Koakutsu A, Fuiyasu N, et al. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol. 2004;492:177–82.

    Article  PubMed  CAS  Google Scholar 

  17. Jarvis MF, Wessale JL, Zhu CZ, et al. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol. 2000;388:29–35.

    Article  PubMed  CAS  Google Scholar 

  18. Bagnato A, Spinella F, Rosano L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer. 2005;12:761–72.

    Article  PubMed  CAS  Google Scholar 

  19. Felx M, Guyot MC, Isler M, Turcotte RE, Doyon J, Khatib AM, et al. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond). 2006;110(6):645–54.

    Article  CAS  Google Scholar 

  20. Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol. 2008;40:1443–51.

    Article  PubMed  CAS  Google Scholar 

  21. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial–mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291(1):59–66.

    Article  PubMed  CAS  Google Scholar 

  22. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944–9.

    Article  PubMed  CAS  Google Scholar 

  23. Herrmann E, Bogemann M, Bierer S, et al. The endothelin axis in urologic tumor: mechanisms of tumor biology and therapeutic implications. Exp Rev Anticancer Ther. 2006;6:73–81.

    Article  CAS  Google Scholar 

  24. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663–8.

    PubMed  CAS  Google Scholar 

  25. Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor A associated with prostate cancer progression. J Urol. 2001;165:1033–6.

    Article  PubMed  CAS  Google Scholar 

  26. Godara G, Cannon GW, Cannon Jr GM, et al. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate. 2005;65:27–34.

    Article  PubMed  CAS  Google Scholar 

  27. Montironi R, Mazzucchelli R, Barbisan F, Stramazotti D, Santinelli A, Lopez-Beltran A, et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol. 2007;52:1682–90.

    Article  PubMed  Google Scholar 

  28. Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001;49:267–77.

    Article  PubMed  CAS  Google Scholar 

  29. Wang Y, Chen J, Li Q, et al. Identifying novel prostate cancer associated pathways based on integrative microarray data analysis. Comput Biol Chem. 2011;35(3):151–8.

    Article  PubMed  CAS  Google Scholar 

  30. Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1 beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine. 1999;11(2):157–62.

    Article  PubMed  Google Scholar 

  31. Wort SJ, Ito M, Chou P, et al. Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kB binding and histone acetylation at specific kB sites. J Biol Chem. 2009;284(36):24297–305.

    Article  PubMed  CAS  Google Scholar 

  32. Patrikidou A, Vlachostergios PJ, Voutsadakis IA, et al. Inverse baseline expression pattern of the NEP/neuropeptides and NFkB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int. 2011;11(1):13.

    Article  PubMed  CAS  Google Scholar 

  33. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II placebo-controlled trial. J Clin Oncol. 2003;21(4):679–89.

    Article  PubMed  CAS  Google Scholar 

  34. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006;107:530–5.

    Article  PubMed  CAS  Google Scholar 

  35. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA. A phase III randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959–66.

    Article  PubMed  CAS  Google Scholar 

  36. Nelson JB, Lowe W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113(9):2478–87.

    Article  PubMed  CAS  Google Scholar 

  37. Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008;14(19):6270–6.

    Article  PubMed  CAS  Google Scholar 

  38. James ND, Caty A, Payne H, Borre M, Zonnenber BA, Beuzeboc P, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo controlled, randomized phase II trial. BJU Int. 2010;106(7):966–73.

    Article  PubMed  CAS  Google Scholar 

  39. Nelson JB, Fizazi K, Miller K, Higano CS, Moul JW, Morris T et al. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer. J Clin Oncol 2011;29(suppl 7; abstr 117).

  40. Grande M, Carlstrom K, Stege R, Pousette A, Faxen M. Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells. Eur Urol. 2002;41(5):568–72.

    Article  PubMed  CAS  Google Scholar 

  41. Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001;49(4):267–77.

    Article  PubMed  CAS  Google Scholar 

  42. Strijbos MH, Gratama JW, Schmitz PI, et al. Circulating endothelial cells, circulating tumor cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer. 2010;46(11):2027–35.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Medical Oncology Department, Translational Oncology Unit, University Hospital La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain

    Álvaro Pinto, María Merino, Pilar Zamora, Andrés Redondo, Beatriz Castelo & Enrique Espinosa

Authors
  1. Álvaro Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Merino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pilar Zamora
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrés Redondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Beatriz Castelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enrique Espinosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Álvaro Pinto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pinto, Á., Merino, M., Zamora, P. et al. Targeting the endothelin axis in prostate carcinoma. Tumor Biol. 33, 421–426 (2012). https://doi.org/10.1007/s13277-011-0299-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0299-6

Keywords

Search

Navigation